AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/β-catenin signaling pathway activity

Abstract

Adenosine monophosphate-activated protein kinase (AMPK) is a principal regulator of metabolism and the conservation of energy in cells, and protects them from exposure to various stressors. AMPK activators may exhibit therapeutic potential as suppressors of cell growth; however, the molecular mechanism underlying this phenomenon in various cancer cells remains to be fully elucidated. The present study investigated the effects of AMPK activators on breast cancer cell growth and specified the underlying molecular mechanism. In the present study, the AMPK activator metformin impaired breast cancer cell growth by reducing dishevelled segment polarity protein 3 (DVL3) and β‑catenin levels. Western blotting and immunohistochemistry demonstrated that DVL3 was recurrently upregulated in breast cancer cells that were not treated with metformin, and was significantly associated with enhanced levels of β‑catenin, c‑Myc and cyclin D1. Overexpression of DVL3 resulted in upregulation of β‑catenin and amplification of breast cancer cell growth, which confirmed that Wnt/β‑catenin activation via DVL3 is associated with breast cancer oncogenesis. To elucidate the underlying mechanism of these effects, the present study verified that metformin resulted in a downregulation of DVL3 and β‑catenin in a dose‑dependent manner, and induced phosphorylation of AMPK. Compound C is an AMPK inhibitor, which when administered alongside metformin, significantly abolished the effects of metformin on the reduction of DVL3 and activation of the phosphorylation of AMPK. Notably, the effects of metformin on the mRNA expression levels of DVL3 remain to be fully elucidated; however, a possible interaction with DVL3 at the post‑transcriptional level was observed. It has previously been suggested that the molecular mechanism underlying AMPK activator‑induced suppression of breast cancer cell growth involves an interaction with, and impairment of, DVL3 proteins. The results of the present study are of future clinical importance and advocate the use of metformin as a potential therapeutic agent against breast cancer.

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells

“…In general, activation of AMPK acts as a sensor of energy status and a mediator of energy homeostasis; therefore, it is possible that IM‐mediated suppression of glycolysis disturbs the intracellular energy balance and activates AMPK. Several studies suggest that inhibiting the mTORC1 and Wnt/β‐catenin signaling pathways, which act downstream of AMPK activation, has anti‐cancer effects . There is little information about the relationship between AMPK and TKI, but we assume that activating AMPK by continuous exposure to IM might increase sensitivity to TKI by affecting the above signaling pathways.…”

“…Several studies suggest that inhibiting the mTORC1 and Wnt/b-catenin signaling pathways, which act downstream of AMPK activation, has anti-cancer effects. 41,42 There is little information about the relationship between AMPK and TKI, but we assume that activating AMPK by continuous exposure to IM might increase sensitivity to TKI by affecting the above signaling pathways.…”

Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway

“…FZD/LRP receptors together with DVL are intrinsic key players in the Wnt/β-catenin pathway. Studies have shown that alteration of these targets regulates the pathway activity in cancers including HCC [ 13 , 31 , 40 ]. Overexpression of these targets serves to activate Wnt/β-catenin signaling.…”

Molecular targets of curcumin in breast cancer (Review)

“…Targets of curcumin in Wnt/β-catenin signaling. Wnts are a family of secreted glycoproteins that regulate multiple signaling pathways through β-catenin-dependent and -independent mechanisms (65)(66)(67). Wnts serve a crucial role in development, survival and metabolism.…”